FDA Approval for Denali Therapeutics Blazes a New Trail for Brain-Penetrating Drugs

Frank Vinluan / medcitynews - Denali Therapeutics’ Avlayah received FDA approval for treating Hunter syndrome, a rare neurological disorder. The biologic medicine uses Denali’s proprietary drug delivery technology to cross the protective blood-brain barrier. The post FDA Approval for …

AI Summary: Regulators granted Denali accelerated approval for a brain‑penetrant therapy, recognizing promising early efficacy in a rare neurological indication and addressing unmet needs in CNS drug delivery. The pathway requires confirmatory trials to verify clinical benefit while enabling earlier patient access to a novel mechanism targeting central nervous system disease.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 13 days

Analysis finds anti-amyloid Alzheimer's drugs lack meaningful benefit / 6 wks

FDA clears first once‑weekly basal insulin for Type 2 diabetes / 2 months

FDA approves Rocket Pharma gene therapy for ultra‑rare immune disorder / 2 months

FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 4 months

FDA rejects Corcept’s cortisol modulator triggering setback / 4 months

FDA approves Rucaparib for advanced prostate cancer / 5 months